Global Respiratory Syncytial Virus (RSV) Therapeutics Market Growth Analysis 2024 — Forecast Market Size And Key Factors Driving Growth
Overview and Scope
Respiratory syncytial virus (RSV) therapeutics refers to the treatments and medications employed to manage and treat infections caused by the respiratory syncytial virus. Respiratory syncytial virus is a common respiratory virus that can cause mild to severe respiratory illness, particularly in infants, young children, older adults, and individuals with weakened immune systems.
Sizing and Forecast
The respiratory syncytial virus (rsv) therapeutics market size has grown exponentially in recent years. It will grow from $1.27 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 25.2%. The growth in the historic period can be attributed to disease awareness, advancements in virology, pediatric vulnerability, epidemic outbreaks, vaccine development.
The respiratory syncytial virus (rsv) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $3.69 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period can be attributed to biologic therapies innovation, emerging antivirals, focus on elderly population, maternal immunization strategies, global research collaborations. Major trends in the forecast period include monoclonal antibodies advancements, nasal vaccines and delivery systems, combination therapies, novel drug delivery systems, home-based treatment options.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report
Segmentation & Regional Insights
The respiratory syncytial virus (rsv) therapeutics market covered in this report is segmented –
1) By Drug: Palivizumab, Ribavirin, Other Drugs
2) By Treatment: Immune Prophylaxis, Supportive Care, Antiviral Medications
3) By Dosage Form: Oral, Injectable, Other Dosage Forms
4) By Patient Type: Pediatrics, Adults
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (rsv) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12601&type=smp
Major Driver Impacting Market Growth
The rise in the prevalence of RSV infection is driving the growth of the respiratory syncytial virus (RSV) therapeutics market going forward. RSV is a prevalent respiratory illness that can result in mild to severe respiratory infections, especially in newborns, young children, elderly adults, and people with compromised immune systems. Increasing RSV infections prompt the development of innovative treatments to address the rising need and mitigate the severity of RSV-related complications. For instance, in September 2022, according to the article published by The Lancet, a UK-based book and periodic data publishing organization, around 11,255 new cases of RSV were recorded in the 2021 summer, which is 9.50% more compared to 10,280 cases in winter 2020–21. Therefore, the rise in the prevalence of RSV infection propels the growth of the respiratory syncytial virus (RSV) therapeutics market.
Key Industry Players
Major companies operating in the respiratory syncytial virus (rsv) therapeutics market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Dr. Reddy’s Laboratories Ltd., Bio-Rad Laboratories Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd
The respiratory syncytial virus (rsv) therapeutics market report table of contents includes:
1. Executive Summary
2. Respiratory Syncytial Virus (RSV) Therapeutics Market Characteristics
3. Respiratory Syncytial Virus (RSV) Therapeutics Market Trends And Strategies
4. Respiratory Syncytial Virus (RSV) Therapeutics Market — Macro Economic Scenario
5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size and Growth
.
.
.
32. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Benchmarking
33. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Respiratory Syncytial Virus (RSV) Therapeutics Market
35. Respiratory Syncytial Virus (RSV) Therapeutics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model